Journal article
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data
FC Bidard, DJ Peeters, T Fehm, F Nolé, R Gisbert-Criado, D Mavroudis, S Grisanti, D Generali, JA Garcia-Saenz, J Stebbing, C Caldas, P Gazzaniga, L Manso, R Zamarchi, AF de Lascoiti, L De Mattos-Arruda, M Ignatiadis, R Lebofsky, SJ van Laere, F Meier-Stiegen Show all
Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2014
Abstract
Background: We aimed to assess the clinical validity of circulating tumour cell (CTC) quantification for prognostication of patients with metastatic breast cancer by undertaking a pooled analysis of individual patient data. Methods: We contacted 51 European centres and asked them to provide reported and unreported anonymised data for individual patients with metastatic breast cancer who participated in studies between January, 2003, and July, 2012. Eligible studies had participants starting a new line of therapy, data for progression-free survival or overall survival, or both, and CTC quantification by the CellSearch method at baseline (before start of new treatment). We used Cox regression ..
View full abstractGrants
Awarded by European Commission
Funding Acknowledgements
Janssen Diagnostics, the Nuovo-Soldati foundation for cancer research.